GISELA CHIN: Open Payments
NPI 1760131486 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,847 in 98 payments from 19 companies in 2025. Trend: 2023 $18 · 2024 $209 · 2025 $1,847
Food & beverage: $1,763Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $695 |
| PFIZER INC. | 18 | $247 |
| Janssen Biotech, Inc. | 11 | $244 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $88 |
| Phathom Pharmaceuticals, Inc. | 3 | $76 |
| GENZYME CORPORATION | 4 | $70 |
| Lilly USA, LLC | 2 | $62 |
| Celltrion USA Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Gilead Sciences, Inc. | 2 | $49 |
Products named: TREMFYA, RINVOQ, SKYRIZI, VELSIPITY, CREON, LINZESS, DUPIXENT, VOQUEZNA.
Industry payments across NV — which companies pay providers there.
